Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma [PDF]
, 2013 This study aimed at determining the recommended dose of the mammalian target of rapamycin inhibitor everolimus in combination with mitomycin C (MMC) in patients with previously treated metastatic esophagogastric cancer.
Atmaca, Akin +5 more
core +1 more source
Mucosal dendritic cells shape mucosal immunity [PDF]
Experimental & Molecular Medicine, 2014 Dendritic cells (DCs) are key modulators that shape the immune system. In mucosal tissues, DCs act as surveillance systems to sense infection and also function as professional antigen-presenting cells that stimulate the differentiation of naive T and B cells.
Chang, Sun-Young +2 more
openaire +2 more sources
Clinical Nutrition Open Sciences u m m a r y: Purpose: Chemotherapy-induced intestinal mucositis is a debilitating condition often triggered by 5-fluorouracil (5-FU). This study investigated the effect of vitamin C alone and combined with L-arginine, in a murine model of 5-FU-induced
Amanda Dias Borges +15 more
doaj +1 more source
Methotrexate and mucositis: A merry-go-round for oncologists
Indian Journal of Medical and Paediatric Oncology, 2019 High-dose methotrexate is the backbone of various regimens for treating lymphoid malignancies. Mucositis is a well-known, dose-related side effect of methotrexate.
Kundan Mishra +6 more
doaj +1 more source
National Journal of Maxillofacial Surgery, 2020 Oral mucositis is one of the most common complications of cancer therapy. It is a nonhematologic complication of cytotoxic chemotherapy and radiotherapy and reduces the quality of life. It is estimated that 40% the cases on standard chemotherapy may develop oral mucositis.
Singh, Vibha, Singh, Akhilesh Kumar
openaire +3 more sources
Treatment of oral mucositis due to chemotherapy [PDF]
, 2016 Introduction: The management of oral mucositis is a challenge, due to its complex biological nature. Over the last 10 years, different strategies have been developed for the management of oral mucositis caused by chemotherapy in cancer patients. Material
Bagán Sebastián, José Vicente +1 more
core +1 more source
Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis
Integrative Cancer Therapies, 2018 Background: Chemoradiotherapy-associated mucositis can manifest as pain, inflammation, dysphagia, diarrhea, weight loss, rectal bleeding, and infection. Mucositis is a major dose-limiting side effect of chemotherapy, affecting nutritional intake and oral
Michael Thomsen MSc, Luis Vitetta PhD
doaj +1 more source
High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer [PDF]
, 2005 Background: Docetaxel is one of the most effective antitumor agents currently available for the treatment of metastatic breast cancer (MBC). This phase II multicenter study prospectively analyzed the efficacy and toxicity of docetaxel given on a weekly ...
Ajani JA +26 more
core +1 more source
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. [PDF]
, 2016 In recent years oral mucosal injury has been increasingly recognized as an important toxicity associated with mammalian target of rapamycin (mTOR) inhibitors, including in patients with breast cancer who are receiving everolimus.
Campbell-Baird, Cynthia +12 more
core
A new concurrent chemotherapy with vinorelbine and mitomycin C in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck [PDF]
, 2005 Objective: The purpose of this pilot study was to evaluate the feasibility and toxicity of concurrent chemotherapy with vinorelbine and mitomycin C in combination with accelerated radiotherapy (RT) in patients with locally advanced cancer of the head and
Bernier J +25 more
core +1 more source